skip to content
Detailed Quote
5i Report
Rating
B

Review of Knight Therapeutics

SEP 03, 2021 - For years, GUD sat on over $700 million in cash and investors awaited big acquisitions. GUD has now made two after investors simply got ‘bored’ of the stock. We do not think management
has done anything wrong, but the delay caused high opportunity costs for investors. Rating downgraded to ‘B’.

Download Report
Company Profile
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions

Q: Good morning, I have 32 positions spread between the two TFSA's that I manage. I'd like to get that down to 25. The above are holdings that have fallen to less than half positions and I'm wondering if you could suggest 6 or 7 for removal. Also are there any that you would add to in order to bring them up to half positions. Secondly, without knowing my weightings, do you have a suggested sector or two for this years TFSA contribution?

Read Answer Asked by Rod on January 06, 2022

Q: Howdy to all you Santa's helpers, thanks for all your wise council.
My question today is: i recently sold GUD after a long hold and so am looking for another healthcare replacement. I know you have reported on NBLY and AND and so wondering which of the two you would recommend to replace GUD. Or, do you have a better recommendation?

Thanks to all

Read Answer Asked by ralph on December 22, 2021
Insiders
Share Information
News and Media